NOX1 and diabetes mellitus: In Apoe+ mouse models with induced diabetes, either genetic deletion of Nox1 or pharmacological inhibition with GKT137831 (setanaxib, a dual NOX1/NOX4 inhibitor) result in a significant reduction in the atherosclerotic burden [105].